Details of Drug-Drug Interaction
| Drug General Information (ID: DDI32XOBAT) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Solifenacin | Drug Info | Mirabegron | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Antispasmodics | Urinary Antispasmodics | |||||||
| Structure | |||||||||
| Mechanism of Solifenacin-Mirabegron Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Increased risk of other adverse reactions (Unspecific) Click to Show/Hide Mechanism Graph | |||||||||
| Drug Name | Solifenacin | Mirabegron | |||||||
| Mechanism | Urinary retention | Urinary retention | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Adverse reactions | ||||||||
| Factor Description | An adverse reaction is an unexpected negative reaction to a medication or treatment that happens even when it's used correctly. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Caution is advised if mirabegron is prescribed in combination with antimuscarinic medications used for the treatment of overactive bladder. | ||||||||
| References | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL. | ||||||||||||||||||